Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.19.3.a.u2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)        
Revenues
Operating expenses:        
General and administrative 89,481 64,385 239,978 227,153
Total operating expenses 89,481 64,385 239,978 227,153
Loss from operations (89,481) (64,385) (239,978) (227,153)
Other income (expense):        
Gain on fair value adjustment - derivatives 200 3,400
Interest expense (126,825) (65,193) (244,812) (197,409)
Amortization - debt discount (4,033) (19,866) (4,533)
Total other income (expense) (126,625) (69,226) (261,278) (201,942)
Loss before provision for income taxes (216,106) (133,611) (501,256) (429,095)
Provision for income tax
Net loss (216,106) (133,611) (501,256) (429,095)
Net loss attributable to noncontrolling interest 763 769 2,348 2,394
Net loss attributable to TranBiotec, Inc. $ (215,343) $ (132,842) $ (512,117) $ (426,701)
Net loss per share        
(Basic and fully diluted) $ (0.001) $ (0.001) $ (0.003) $ (0.004)
Weighted average number of common shares outstanding 165,167,345 116,751,078 153,621,523 113,797,952